SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)

Small-cell lung cancer (SCLC) is a highly aggressive malignancy comprising approximately 15% of lung cancers. Only one-third of patients are diagnosed at limited-stage (LS). Surgical resection can be curative in early stages, followed by platinum-etoposide adjuvant therapy, although only a minority...

Descripción completa

Detalles Bibliográficos
Autores: Garcia-Campelo, R, Sullivan, I, Arriola, E, Insa, A, Vidal, O, Cruz-Castellanos, P, Moran, T, Reguart, N, Zugazagoitia, J, Domine, M
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p16342
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=16342
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85164117101&doi=10.1007%2fs12094-023-03216-3&partnerID=40&md5=753a025cf7626f9dd2da0f4ad197d6e9
Access Level:acceso abierto
Palabra clave:Small-cell lung cancer
Clinical practice guidelines
Diagnosis
Treatment
Follow-up
id ES_eb307684085d393b221fc0aaa3a308fe
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p16342
network_acronym_str ES
network_name_str España
repository_id_str
spelling SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)Garcia-Campelo, RSullivan, IArriola, EInsa, AVidal, OCruz-Castellanos, PMoran, TReguart, NZugazagoitia, JDomine, MSmall-cell lung cancerClinical practice guidelinesDiagnosisTreatmentFollow-upSmall-cell lung cancer (SCLC) is a highly aggressive malignancy comprising approximately 15% of lung cancers. Only one-third of patients are diagnosed at limited-stage (LS). Surgical resection can be curative in early stages, followed by platinum-etoposide adjuvant therapy, although only a minority of patients with SCLC qualify for surgery. Concurrent chemo-radiotherapy is the standard of care for LS-SCLC that is not surgically resectable, followed by prophylactic cranial irradiation (PCI) for patients without progression. For extensive-stage (ES)-SCLC, a combination of platinum and etoposide has historically been a mainstay of treatment. Recently, the efficacy of programmed death-ligand 1 inhibitors combined with chemotherapy has become the new front-line standard of care for ES-SCLC. Emerging knowledge regarding SCLC biology, including genomic characterization and molecular subtyping, and new treatment approaches will potentially lead to advances in SCLC patient care.SPRINGER INTERNATIONAL PUBLISHING AG2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=16342https://www.scopus.com/inward/record.uri?eid=2-s2.0-85164117101&doi=10.1007%2fs12094-023-03216-3&partnerID=40&md5=753a025cf7626f9dd2da0f4ad197d6e9Clinical & Translational OncologyISSN: 1699048XISSNe: 16993055reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p163422026-06-14T12:41:47Z
dc.title.none.fl_str_mv SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)
title SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)
spellingShingle SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)
Garcia-Campelo, R
Small-cell lung cancer
Clinical practice guidelines
Diagnosis
Treatment
Follow-up
title_short SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)
title_full SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)
title_fullStr SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)
title_full_unstemmed SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)
title_sort SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)
dc.creator.none.fl_str_mv Garcia-Campelo, R
Sullivan, I
Arriola, E
Insa, A
Vidal, O
Cruz-Castellanos, P
Moran, T
Reguart, N
Zugazagoitia, J
Domine, M
author Garcia-Campelo, R
author_facet Garcia-Campelo, R
Sullivan, I
Arriola, E
Insa, A
Vidal, O
Cruz-Castellanos, P
Moran, T
Reguart, N
Zugazagoitia, J
Domine, M
author_role author
author2 Sullivan, I
Arriola, E
Insa, A
Vidal, O
Cruz-Castellanos, P
Moran, T
Reguart, N
Zugazagoitia, J
Domine, M
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Small-cell lung cancer
Clinical practice guidelines
Diagnosis
Treatment
Follow-up
topic Small-cell lung cancer
Clinical practice guidelines
Diagnosis
Treatment
Follow-up
description Small-cell lung cancer (SCLC) is a highly aggressive malignancy comprising approximately 15% of lung cancers. Only one-third of patients are diagnosed at limited-stage (LS). Surgical resection can be curative in early stages, followed by platinum-etoposide adjuvant therapy, although only a minority of patients with SCLC qualify for surgery. Concurrent chemo-radiotherapy is the standard of care for LS-SCLC that is not surgically resectable, followed by prophylactic cranial irradiation (PCI) for patients without progression. For extensive-stage (ES)-SCLC, a combination of platinum and etoposide has historically been a mainstay of treatment. Recently, the efficacy of programmed death-ligand 1 inhibitors combined with chemotherapy has become the new front-line standard of care for ES-SCLC. Emerging knowledge regarding SCLC biology, including genomic characterization and molecular subtyping, and new treatment approaches will potentially lead to advances in SCLC patient care.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=16342
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85164117101&doi=10.1007%2fs12094-023-03216-3&partnerID=40&md5=753a025cf7626f9dd2da0f4ad197d6e9
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=16342
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85164117101&doi=10.1007%2fs12094-023-03216-3&partnerID=40&md5=753a025cf7626f9dd2da0f4ad197d6e9
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SPRINGER INTERNATIONAL PUBLISHING AG
publisher.none.fl_str_mv SPRINGER INTERNATIONAL PUBLISHING AG
dc.source.none.fl_str_mv Clinical & Translational Oncology
ISSN: 1699048X
ISSNe: 16993055
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423206030376960
score 15,812455

Similares en LA Referencia